| Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767) |
|---|
| 03/26/2009 | US20090082364 Deuterium-enriched levocedtirizine |
| 03/26/2009 | US20090082362 Use of capsaicin receptor antagonists to treat symptoms of tear gas exposure |
| 03/26/2009 | US20090082329 Novel Sulphur-Containing Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors |
| 03/26/2009 | US20090082319 Deuterium-enriched budesonide |
| 03/26/2009 | US20090082318 Deuterium-enriched mometasone |
| 03/26/2009 | US20090082287 Methods of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes |
| 03/26/2009 | US20090081780 Canine respiratory coronavirus (crcv) spike protein, polymerase and hemagglutinin/esterase |
| 03/26/2009 | US20090081732 Antibodies to human il-1beta |
| 03/26/2009 | US20090081283 Tumor therapy with non-viral-based high affinitiy laminin receptor-targeted vectors |
| 03/26/2009 | US20090081239 bind and neutralize Plasminogen Activator Inhibitor-1 (PAI-1) by converting PAI-1 to its latent form or increasing proteolytic cleavage; treating a fibrotic condition; inhibits accumulation of extracellular matrix (ECM) |
| 03/26/2009 | US20090081131 Tumor therapy with high affinity laminin receptor-targeted vectors and compounds |
| 03/26/2009 | US20090081126 Novel fully human anti-VAP-1 monoclonal antibodies |
| 03/26/2009 | US20090081123 Pharmaceutical compounds |
| 03/26/2009 | CA2699909A1 Process for preparing 1,3-dioxolan-2-ones as well as carboxylic acid esters by transacylation under basic reaction conditions |
| 03/26/2009 | CA2695435A1 Combination of nitroderivatized steroid and bronchodilator for treating respiratory disease |
| 03/25/2009 | EP2039700A2 Novel anti-inflammatory androstane derivatives |
| 03/25/2009 | EP2039361A2 Use of immunomodulatory compounds |
| 03/25/2009 | EP2038277A2 Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound |
| 03/25/2009 | EP2037916A2 Pure isomers of tritoqualine |
| 03/25/2009 | EP2037915A2 Phenol derivatives for the treatment of respiratory diseases |
| 03/25/2009 | EP2037912A2 Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist |
| 03/25/2009 | EP2000473A9 Trehalose compound and pharmaceutical comprising the compound |
| 03/25/2009 | EP2000469A9 Acylaminopiperidine compound |
| 03/25/2009 | EP1377579B1 Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents |
| 03/25/2009 | EP1299421B1 Antibodies to human mcp-1 |
| 03/25/2009 | CN101395150A Phenethanolamine derivatives as beta2 adrenoreceptor agonists |
| 03/25/2009 | CN101395147A 1-(benzo (d) (1,3) dioxol-5-yl) -n- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis |
| 03/25/2009 | CN101392001A Carboxamides derivates, preparation method thereof and use on medicine |
| 03/25/2009 | CN101391965A Method for preparing terbutaline sulphate crystal B fulfilling medicinal requirements |
| 03/25/2009 | CN101391102A Production technique of immunoglobulin compounding agent capable of preventing and treating poultry respiratory disease |
| 03/25/2009 | CN101391075A Mixed traditional Chinese medicine health-care pillow |
| 03/25/2009 | CN101391058A Preparation for clearing away the heat-evil and expelling superficial evils |
| 03/25/2009 | CN101391024A Traditional Chinese medicine capsule for treating emphysema, tracheitis, asthma and cough and syrup |
| 03/25/2009 | CN101391020A Traditional Chinese medicine liquor for treating idiopathic pulmonary fibrosis and preparation method thereof |
| 03/25/2009 | CN101390992A Asthma oral liquid and its preparing process |
| 03/25/2009 | CN101390991A Medicine for treating coryza, chronic nasal sinusitis |
| 03/25/2009 | CN101390984A Quality control method of Lanhuayao |
| 03/25/2009 | CN101390982A Traditional Chinese medicine prescription for treating rhinitis |
| 03/25/2009 | CN101390977A Oral liquid special for treating acute tonsillitis |
| 03/25/2009 | CN101390976A Traditional Chinese medicine composing prescriptions for treating pulmonary heart disease |
| 03/25/2009 | CN101390959A Disinfector for treating nasal vestibule, dryness of nasal cavity and skin burn and scald |
| 03/25/2009 | CN101390956A Double coptis injection and preparation method thereof |
| 03/25/2009 | CN101390868A Plant polysaccharide and preparation method and use thereof |
| 03/25/2009 | CN101390864A Specific medicine capable of curing cold after three or four days |
| 03/25/2009 | CN101390862A Medicine composition containing mizolastine and preparation method thereof |
| 03/25/2009 | CN101390860A Desloratadine syrup and preparation method thereof |
| 03/25/2009 | CN101390849A Allitride composition and method thereof for preparing drop capable of treating nasal cavity microbial infection and use thereof |
| 03/25/2009 | CN100471945C Novel avian disease bacteria and bacterin derived therefrom |
| 03/25/2009 | CN100471871C Therapeutic human anti-IL-1R1 monoclonal antibody |
| 03/25/2009 | CN100471838C VLA-4 inhibitors |
| 03/25/2009 | CN100471495C Fumaric acid-ketotifen dispersion tablet and its prepn process |
| 03/24/2009 | US7507841 Cannabinoid receptor modulator |
| 03/24/2009 | US7507795 Zcytor17 ligand cytokine; immunostimulators system, and proliferation and/or development of hematopoietic cells in vitro and in vivo; transcription, gene expression, culturing; anticarcinogenic and antiinflammatory agents; diabetes, pancreatitis, inflammatory bowel disease; autoimmune diseases |
| 03/24/2009 | US7507767 Sulfonamide-containing benzene derivatives which exhibit anti-inflammatory and immunodulatory activity |
| 03/24/2009 | US7507759 Methods of using(+)-2-[1-(3-ethoxy-4methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3,-dione |
| 03/24/2009 | US7507747 Muscarinic acetylcholine receptor antagonists |
| 03/24/2009 | US7507741 Heterocyclic compounds |
| 03/24/2009 | US7507730 Substituted pyrazolo[1,5-a]pyrimidines as potassium channel activators |
| 03/24/2009 | US7507706 Administering a polypeptide to reduce airway hyper responsiveness or reduce the increase of mucus-containing cells in the airway epithelium; IL-13 binding chains of the interleukin-13 receptor |
| 03/24/2009 | US7507542 Autoimmune diseases; inflammatory bowel disease; multiple sclerosis; rheumatic diseases; modulate gene expression |
| 03/24/2009 | US7507414 Therapeutic polypeptide with prolonged shelf-life and increased half life for use in treatment of cell proliferative, cardiovascular, inflammatory and autoimmune disorders |
| 03/24/2009 | CA2422380C Pyrazole compounds useful as protein kinase inhibitors |
| 03/24/2009 | CA2356745C Ionic aqueous composition containing levomenthol |
| 03/19/2009 | WO2009036243A1 Novel combination of therapeutic agents |
| 03/19/2009 | WO2009035598A1 Deuterated pirfenidone |
| 03/19/2009 | WO2009035068A1 Novel 1,3,3-trimethyl-7-phenyl-3,4-dihydro-1h-quinoxalin- 2-one derivatives |
| 03/19/2009 | WO2009035067A1 Glucocorticoid receptor agonists consisting of 1,3,3-tri- methyl-7-phenyl-3,4-dihydro-1h-quinoxalin-2-one derivatives |
| 03/19/2009 | WO2009033824A1 Use of a combination of beta-casokinin and cnp-22 as a therapeutic agent |
| 03/19/2009 | WO2009033823A1 Use of a peptide combination comprising urotensin ii as a therapeutic agent |
| 03/19/2009 | WO2009033822A2 Use of a combination of a cathepsin g fragment and teprotide as a therapeutic agent |
| 03/19/2009 | WO2009033821A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033820A2 Use of saralasin and carbetocin in combination to treat of eg aids or idiopathic pulmonary fibrosis |
| 03/19/2009 | WO2009033819A2 Use of glicentin-related polypeptide and apelin- 13 in combination as therapeutic agents, eg for treating aids |
| 03/19/2009 | WO2009033818A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033817A2 Use of the combination of the hcv-1 e2 protein (484-499) and the human pancreatic polypeptide as a therapeutic agent |
| 03/19/2009 | WO2009033816A2 Use of the combination of thymosin beta 10 and thymosin alpha 1 peptides as a therapeutic agent |
| 03/19/2009 | WO2009033815A2 Use of the peptide combination ala-pro-gly-pro-arg with cecropin a as a therapeutic agent |
| 03/19/2009 | WO2009033814A2 Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent |
| 03/19/2009 | WO2009033813A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033812A2 Use of a combination of neuropeptide-ff and alpha-msh as a therapeutic agent |
| 03/19/2009 | WO2009033811A2 Therapeutic uses of muroctasin and kisspeptin13 and compositions thereof |
| 03/19/2009 | WO2009033810A2 Use of antioxidant peptide a (phckrm) and aplha-casein (90-96) as therapeutic agents in eg the treatment of hiv infection |
| 03/19/2009 | WO2009033809A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033807A2 Therapeutic uses of b-type natriuretic peptide and human growth hormone 1-43 |
| 03/19/2009 | WO2009033806A2 Use of gly-pro-glu-oh (gpe) as a therapeutic agent |
| 03/19/2009 | WO2009033805A2 Use of somatostatin-14 as a therapeutic agent |
| 03/19/2009 | WO2009033804A2 Use of gamma- endorphin as a therapeutic agent |
| 03/19/2009 | WO2009033803A2 Use of the pentapeptide drlds and gamma-endorphin as therapeutic agents |
| 03/19/2009 | WO2009033802A2 Antide as a therapeutic agent |
| 03/19/2009 | WO2009033801A2 Syndyphalin alone or in combination with antide as a therapeutic agent |
| 03/19/2009 | WO2009033800A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033799A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033798A1 Combination of motilin and minigastrin as a therapeutic agent |
| 03/19/2009 | WO2009033797A2 Use of apelin-17 and peptide yy as therapeutic agents, eg for treating hbv infection |
| 03/19/2009 | WO2009033796A1 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033795A2 Use of a obestatin as a therapeutic agent |
| 03/19/2009 | WO2009033793A2 Pentagastrin as a therapeutic agent |
| 03/19/2009 | WO2009033792A2 Gamma 1 msh alone or in combination with pentagastrin as a therapeutic agent |
| 03/19/2009 | WO2009033791A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033790A2 Use of a peptide as a therapeutic agent |